Member Info for Bella6532

Https://www.medicxi.com/news/medicxi-launches-first-300m-late-stage-life-sciences-fund-medicxi-growth-1-mg1-backed-by-novartis-and-verily

Now this us why I was talking about Novartis...to get you to Medicxi....

Check out the second news item in this link...

https://www.medicxi.com/news-room

Yes our own Eliot Foster...

It's a General Meeting not an AGM...

Check out Simon Bennett at Simon Bennett Associates Ltd LinkedIn page...no mention of Avacta?

And didn't anyone wonder why we changed to ICR Consilium? There's a connection there too.

And again from the Turner Pope Note:

'Understanding that the c.24 months cash runway now

secured should be sufficient to support planning for introduction of the

Group’s first targeted chemotherapy to market before the end of 2026, the

Board’s key ambition to retain 100% ownership of its pre|CISION™ platform

looks likely to be realised.'

This is an interesting statement: the Board’s key ambition to retain 100% ownership of its pre|CISION™ platform

looks likely to be realised'

So..why a fundraiser at 0.50? ...someone wanted in at this price...and only a big II (fund) could demand such a price discount.

How does a fundraise at such a discounted price guarantee 100% ownership of PreCISION unless someone big was on the inside to help support and protect it like a big fund.

Why did they mention in the RNS that a a European specialist healthcare fund had participated...they didn't have to.

Why did three key Directors invest too...mmmm! a fund might insist on seeing their commitment too...

Why £20m....Novatis also say: 'Our investment strategy

We specialize in investments ranging from USD 5-10 million, primarily focusing on Seed and Series A stage companies. However, we remain open to exploring later-stage opportunities as well. We allocate up to USD 25 million for each company we engage with, allowing us to provide substantial support across various growth phases.'

Why be so specific as to where the money will be spent...ring fencing?

Why the AS comment about funding not being a problem ...and we would like it...look at these two statem ent with different lenses...the funding was to allow a fund in like Novatis...and we would like it...of course we would once we are told who it really is and perhaps see a Novatis fund member on our Board and the news gets out to the wider market and we see a nice jump in the SP knowing our IP is protected from T/O for now....

Guys...it's never what they say it's what they don't say which is important...RNS's always contain the clues...

As I said...far more to this than we might think.

Oh and FYI...'Dr. Coughlin has held other leadership roles in the pharmaceutical and biotechnology fields in her career including Oncology Asset Team Leader at Pfizer and Clinical Program Team Lead at Novartis.'

and Novartis also say..'.While we do work with innovative life science companies and teams developing novel therapeutics and platforms in the biotechnology and biopharma space, we do not invest in medtech or diagnostics.

Addressing unmet patient needs is our overriding ambition. We want not only to deliver significant return, but also to create real clinical impact.'

I guess we'll find out on 18th/19th March...

'The Novartis Venture Fund team’s approach to investing

We prefer an active, hands-on style of investment, one major element of which involves taking a seat on the company board. This enables us to collaborate closely with leadership and management.'

From the Turner Pope Note:

'Proceeds in excess of c.£20m, including any raised through the REX Offer and

surplus cash are expected to extend the cash runway well into 2026 and be

directed toward completing investigational new drug (‘IND’) enabling studies,

submitting an IND/clinical trial application and initiating a Phase 1a dose

escalation study for AVA3996, while progressing the pre|CISION™ and

Affimer® pre-clinical pipelines.'

and the PIPELINE is not just PreCISION....

https://avacta.com/therapeutics/pipeline/

So again my questions is....What is the next product announcement and why not until later this year...?

and Why the sudden urgency?

Note: 'Apicell Therapeutics, now in its 4th year of founding, is currently preparing for phase 1 clinical trials in the U.S. for its lead pipeline 'AFX001'.

IN THE US....mmmm!

Perhaps it's this guy who needs to take the blame for bad coms....

Michael Vinegrad

Group Communications Director

With almost 20 years experience in healthcare and life sciences marketing and communications, Michael previously worked for the NHS, Department of Health and Smith & Nephew. Here he helped to significantly grow their digital presence and delivered a number of successful international medical device campaigns, as well as working on internal and external corporate communications.

Http://affyxell.com/bbs/?so_table=news&mode=VIEW&num=38&category=&findType=&findWord=&sort1=&sort2=&page=1

Jeon Seung-ho, CEO of Daewoong Pharmaceutical, “Fostering Apicell into a global unicorn”

2024-01-25

FDA clinical pre-meeting… “Achieved 100% performance”

“IPO plan for 2026… Technology exports are also discussed”

Apicell Therapeutics, now in its 4th year of founding, is currently preparing for phase 1 clinical trials in the U.S. for its lead pipeline 'AFX001'.

This will be first in patient Affimer trial and it's not too far away now...

The fundraiser wasn't just about PreCision...there's a lot more going on...

I suspect news will be forthcoming after the fundraise has been completed.

Why haven't Avacta issued an update about goings on with Affyxell...the above link is public knowledge isn't it?

Is this new???

https://emea01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.google.com%2Furl%3Frct%3Dj%26sa%3Dt%26url%3Dhttps%3A%2F%2Fwww.pharmaceutical-technology.com%2Fdata-insights%2Favacta-group-files-patent-for-extended-circulating-serum-half-life-therapeutic-conjugates%2F%26ct%3Dga%26cd%3DCAEYACoSMzYzODQwMjk2NzEzMzA2MzY5Mho4MWJjNTRmYmRiYzVlMjFjOmNvbTplbjpVUw%26usg%3DAOvVaw0DmNMlSwa68ETKK7-f7H7E&data=05%7C02%7C%7C81646e2ec2e0476e0c8b08dc3e638485%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C638453844339876665%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=dVWUEeCq198bFsUqGpkYZnqdheMaOzeAlZmJkxN62t8%3D&reserved=0

Howzaty...not news...I posted a link to the announcement on here a couple of days ago and have been talking about a Partner possibly being the reason...all lost in the noise...

We've got to get 18 March out of the way then news will drop...

.... Yanks and Brits...We might all speak English but we don't all speak the same language...agree...language has to be fined tuned for the US market to understand...

BV ....caveat...I lived and worked in the US for some years having set up an agency/distribution business there covering 8 states within the chemical industry so lots of contact with regulatory bodies etc. The US is very insular and they prefer you to be on their side of the pond...

BV...I suspect it's easier to have the trials done in the US under one team. Even though it might be far more expensive it should be quicker and in the US they like to see companies based in the US...and this is particularly true with the likes of the FDA. It also means they have relevance to US companies/investors when they talk about the trials in news articles/RNS's etc plus their presence in the US certainly won't go unnoticed by the likes of Nasdaq as and when they decide to list.

LivelongnProsper...'Tx programme in good hands with CC leading Avacta Scientists, SAB team, Dr William Tap, Dr Lee Kranmer, et al.'

...agree and they know how the US Regularoty bodies work etc. Note AVA6000 is being trialled in the US now with 2 weekly and P2 going to be stateside...much more expensive...hence need more funds in my opion.

If you check the Turner Pope note...AVA3996 is on there with IND etc end 24/25 and the Pipeline is also mentioned with next clinical candidate selection not until 2025.

So why can't they tell us until later this year what the £11.1m is for???? or are they simply bringing the next candidate selection forward into 2024 - but that's strange because they could have said this in the Turner Pope note...

OK so here's my pennies worth re the pipeline/fundraise. The Poster Presentation is what we expected but it looks like the major shift is to do with the pipeline. Why?

‘…the recent placing aimed to raise approximately £20 million to support the continued clinical development of AVA6000, the first of Avacta's pre|CISIONTM…’

‘Without additional funds in excess of £20m, the Company would not have been able to progress any of its pre-clinical pipeline, which we believe will drive significant future shareholder value well beyond AVA6000’

‘Despite the difficult circumstances surrounding the placing we therefore believe it is in the Company's and shareholders' best interests to raise sufficient funds to both progress AVA6000 and the broader pipeline…’

‘This financing has brought several new high-quality institutions onto the share register including a large European healthcare specialist fund and, subject to the outcome of the general meeting, it provides Avacta with funding to both advance AVA6000 through the clinic as well as developing exciting pre-clinical assets which we look forward to detailing later this year.’

So, with approval at the 18 March General Meeting they will have £31.1m total in new funding:

£20m for AVA6000 and £11.1m to progress the Pre-Clinical pipeline

Now, what do they mean by the broader pipeline?

What do they mean by developing EXCITING Pre-clinical assets but not say what they are? And why can’t they tell us until later this year? Is it due to a third party NDA?

What do they mean by will drive significant future shareholder value beyond AVA6000?

Why target the broader pipeline now and not wait until results from the 2 weekly and even P2? Why the urgency? Who has applied the urgency?

Jan 2022 announced that the next pre|CISIONTM drug candidate, AVA3996, had been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning in the second half of 2023…if it’s this, why not name it?

We also know about the inhouse pipeline:

AVA028 / 032 – PD-L1 Affimer® / ImmunoCytokines

AVA021 – PD-L1 Affimer® / LAG-3 Affimer®

TMAC® platform

But could it be from the inhouse UNDISCLOSED targets

OR

Does is it something to do with our Partners research. LG have undisclosed targets and have they asked Avacta to bring them forward in which case these will now take priority?

OR

Does it have something to do with Daewoong wanting to develop new targets?

It seems to me for whatever reason there has been a definite shift in pipeline emphasis be it internal or from a Partner.